A Phase 1/2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma

Brief description of study

This phase I/II trial studies the side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that cannot be removed by surgery and has not spread to other parts of the body (localized). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving M3814 and hypofractionated radiation therapy together may work better than radiation therapy alone in the treatment of patients with localized pancreatic cancer.


Clinical Study Identifier: s21-00991
ClinicalTrials.gov Identifier: NCT04172532
Principal Investigator: Paul E. Oberstein.
Other Investigators: Rafael Winograd, Theresa Ryan, Jennifer Wu, Daniel J Becker, Cristian C Papazoglu Statescu, Kristen Spencer, Keriann M Scavone, Nina Beri, Lawrence P Leichman, Shun Yu, Mary Lynn R Nierodzik, Fauzia Shaikh.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.